PePS2 Results

Results of the PePS2 trial of pembrolizumab in performance status 2 non-small-cell lung cancer patients published in Lancet Respiratory Medicine.

The PePS2 Trial

PePS2 is a phase II trial of pembrolizumab in performance status 2 non-small-cell lung cancer patients.

The trialr package

_trialr_ is an R package implementing Bayesian clinical trial methods in Stan.

A Phase II Clinical Trial Design for Associated Co-primary Efficacy and Toxicity Outcomes with Baseline Covariates

The experimental design presented here is motivated by a phase II clinical trial called PePS2, investigating the efficacy and safety of an immunotherapy called pembrolizumab in a specific subgroup of lung cancer patients.

trialr - Bayesian Clinical Trial Designs in R and Stan

This manuscript introduces an R package called trialr that implements a collection of clinical trial methods in Stan and R. In this article, we explore three methods in detail...

How to design a dose-finding study using the continual reassessment method

The continual reassessment method (CRM) is a model-based design for phase I trials, which aims to find the maximum tolerated dose (MTD) of a new therapy. The CRM has been shown to be more accurate in targeting the MTD than traditional rule-based approaches such as the 3 + 3 design, which is used in most phase I trials.

Combination Lenalidomide and Azacitidine - A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia

Salvage options for patients who relapse after allogeneic stem-cell transplantation (allo-SCT) for acute myeloid leukemia (AML) and myelodysplasia (MDS) remain limited, and novel treatment strategies are required. Both lenalidomide (LEN) and azacitidine (AZA) possess significant antitumor activity effect in AML.

Implementing the EffTox dose-finding design in the Matchpoint trial

The Matchpoint trial aims to identify the optimal dose of ponatinib to give with conventional chemotherapy consisting of fludarabine, cytarabine and idarubicin to chronic myeloid leukaemia patients in blastic transformation phase. The dose should be both tolerable and efficacious. This paper describes our experience implementing EffTox in the Matchpoint trial.